TheraRadar
← Back
Data updated: Mar 29, 2026

OTSUKA ICU MEDCL

MetabolicOphthalmology
Specialty

OTSUKA ICU MEDCL is a specialty pharmaceutical company focused on Metabolic, Ophthalmology.

1971
Since
68
Drugs
-
Trials
15
Approved (2yr)

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Metabolic 58%
7 drugs
Ophthalmology 42%
5 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...